Raymond James Maintains Outperform on Revolution Medicines, Raises Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Laura Prendergast has maintained an Outperform rating on Revolution Medicines (NASDAQ:RVMD) and increased the price target from $30 to $36.
January 16, 2024 | 12:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James analyst Laura Prendergast has reaffirmed an Outperform rating on Revolution Medicines and raised the price target from $30 to $36.
The increase in price target by a reputable analyst typically signals a positive outlook on the company's future performance, which can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100